FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded in April 2021 and is headquartered in Houston, TX